Stryker (SYK) Cash from Financing Activities (2009 - 2026)
Stryker's (SYK) quarterly Cash from Financing Activities came in at -$95.0 million in Q2 2026, up 90.39% year-over-year from -$49.9 million in Q2 2025, and up 93.71% quarter-over-quarter from -$1.5 billion in Q1 2026.
Analysis
Stryker (SYK) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Stryker (SYK) has reported Cash from Financing Activities for 18 consecutive years, with -$95.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Financing Activities rose 90.39% year-over-year to -$95.0 million in Q2 2026; TTM through Jun 2026 was -$3.0 billion, a 226.33% decrease from a year earlier, with the FY2025 full-year figure at $113.0 million, up 121.52% from the prior year.
- Cash from Financing Activities was -$95.0 million for Q2 2026 at Stryker, up from -$1.5 billion in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $2.7 billion in Q3 2024 and troughed at -$1.8 billion in Q4 2024.
- A 5-year average of -$242.2 million and a median of -$434.0 million in 2022 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 728.67% in 2024, down 527.27% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$446.0 million in 2022, then surged by 35.87% to -$286.0 million in 2023, then slumped by 527.27% to -$1.8 billion in 2024, then surged by 39.07% to -$1.1 billion in 2025, then soared by 91.31% to -$95.0 million in 2026.
- The last three Cash from Financing Activities figures came in at -$95.0 million (Q2 2026), -$1.5 billion (Q1 2026), and -$1.1 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Zimmer Biomet Holdings | 18.20 Bn | 17.79 Bn | 1.54 Bn | -271.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -95.00 Mn |
| Mar 31, 2026 | -1.51 Bn |
| Dec 31, 2025 | -1.09 Bn |
| Sep 30, 2025 | -339.00 Mn |
| Jun 30, 2025 | -989.00 Mn |
| Mar 31, 2025 | 2.53 Bn |
| Dec 31, 2024 | -1.79 Bn |
| Sep 30, 2024 | 2.65 Bn |
| Jun 30, 2024 | -966.00 Mn |
| Mar 31, 2024 | -418.00 Mn |
| Dec 31, 2023 | -286.00 Mn |
| Sep 30, 2023 | -422.00 Mn |
| Jun 30, 2023 | -405.00 Mn |
| Mar 31, 2023 | -481.00 Mn |
| Dec 31, 2022 | -446.00 Mn |
| Sep 30, 2022 | -543.00 Mn |
| Jun 30, 2022 | -753.00 Mn |
| Mar 31, 2022 | 993.00 Mn |
| Dec 31, 2021 | -288.00 Mn |
| Sep 30, 2021 | -348.00 Mn |